Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Stock Chart & Stats
$134.39
-$0.34(-2.31%)
At close: 4:00 PM EST
$134.39
-$0.34(-2.31%)
Day’s Range― - ―
52-Week Range$18.23 - $151.18
Previous CloseN/A
Volume11.83K
Average Volume (3M)369.10K
Market Cap
$1.84B
Enterprise Value$1.54B
Total Cash (Recent Filing)$63.57M
Total Debt (Recent Filing)$16.02M
Price to Earnings (P/E)―
Beta<0.01
Next Earnings
Apr 06, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding13,676,490
10 Day Avg. Volume541,327
30 Day Avg. Volume369,103
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.43
Price to Sales (P/S)0.00
P/FCF Ratio-2.46
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-80.75
Forecast
1Y Price Target
$214.76Price Target Upside59.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.88
Revenue Forecast (FY)$226.67K
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 SELVA showed statistically significant and clinically meaningful improvements across primary and secondary endpoints, supporting strong efficacy for QTORIN rapamycin in microcystic lymphatic malformations.
Intellectual Property And Pipeline ExpansionSpecialized topical formulation backed by issued patents and manufacturing trade secrets creates barriers to compounded alternatives, and the program is positioned to expand into additional indications that currently lack approved therapies.
Physician Adoption And Commercial ReadinessKey opinion leaders and physician survey responses indicate high intent to prescribe QTORIN as a frontline therapy, and the company has initiated commercial and medical affairs hires to engage high-volume treatment centers.
Bears Say
Financial Runway And Dilution RiskAn annualized cash burn near $32 million implies a constrained cash runway on a fully diluted basis, increasing the likelihood of future fundraising that could dilute shareholders.
Pediatric Labeling UncertaintyVery limited enrollment of very young pediatric patients creates uncertainty about labeling for younger children and may require further regulatory discussion or additional studies.
Safety And TolerabilityA patient discontinuation for lymphorrhea and treatment-related application-site effects raise safety and tolerability questions that could prompt additional regulatory review or label precautions.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics’s price range in the past 12 months?
Palvella Therapeutics lowest stock price was $18.23 and its highest was $151.18 in the past 12 months.
What is Palvella Therapeutics’s market cap?
Palvella Therapeutics’s market cap is $1.84B.
When is Palvella Therapeutics’s upcoming earnings report date?
Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 28 days.
How were Palvella Therapeutics’s earnings last quarter?
Palvella Therapeutics released its earnings results on Nov 11, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.838 by -$0.192.
Is Palvella Therapeutics overvalued?
According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued.
Does Palvella Therapeutics pay dividends?
Palvella Therapeutics does not currently pay dividends.
What is Palvella Therapeutics’s EPS estimate?
Palvella Therapeutics’s EPS estimate is -0.91.
How many shares outstanding does Palvella Therapeutics have?
Palvella Therapeutics has 13,676,490 shares outstanding.
What happened to Palvella Therapeutics’s price movement after its last earnings report?
Palvella Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.838. Following the earnings report the stock price went down -3.039%.
Which hedge fund is a major shareholder of Palvella Therapeutics?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$214.76 (59.80% Upside)
$214.76 (59.80% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 193.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $800.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
461.36%
12-Months-Change
Fundamentals
Return on Equity
-64.41%
Trailing 12-Months
Asset Growth
226.17%
Trailing 12-Months
Company Description
Palvella Therapeutics
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q3 2025
0:00 / 0:00
PVLA Stock 12 Month Forecast
Average Price Target
$214.76
▲(59.80% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Tyra Bioscience
―
Ownership Overview
1.83% Insiders
7.59% Mutual Funds
15.22% Other Institutional Investors
65.54% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---